A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had...

Descripción completa

Detalles Bibliográficos
Autores principales: Lancet, JE, Ravandi, F, Ricklis, RM, Cripe, LD, Kantarjian, HM, Giles, FJ, List, AF, Chen, T, Allen, RS, Fox, JA, Michelson, GC, Karp, JE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576993/
https://www.ncbi.nlm.nih.gov/pubmed/21760592
http://dx.doi.org/10.1038/leu.2011.157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576993/
https://www.ncbi.nlm.nih.gov/pubmed/21760592
http://dx.doi.org/10.1038/leu.2011.157

Ejemplares similares